PL2118099T3 - Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy - Google Patents

Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy

Info

Publication number
PL2118099T3
PL2118099T3 PL08708929T PL08708929T PL2118099T3 PL 2118099 T3 PL2118099 T3 PL 2118099T3 PL 08708929 T PL08708929 T PL 08708929T PL 08708929 T PL08708929 T PL 08708929T PL 2118099 T3 PL2118099 T3 PL 2118099T3
Authority
PL
Poland
Prior art keywords
synthesis
kinase inhibitors
aminothiazole compounds
aminothiazole
compounds
Prior art date
Application number
PL08708929T
Other languages
English (en)
Inventor
Alain Moussy
Philippe Reginault
François Bellamy
Anne Lermet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of PL2118099T3 publication Critical patent/PL2118099T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL08708929T 2007-02-13 2008-02-13 Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy PL2118099T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88958707P 2007-02-13 2007-02-13
PCT/EP2008/051704 WO2008098949A2 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
EP08708929A EP2118099B1 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2118099T3 true PL2118099T3 (pl) 2011-12-30

Family

ID=39332208

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11170200T PL2366703T3 (pl) 2007-02-13 2008-02-13 Postać polimorficzna pochodnej 2-amino-(nitroarylo)-tiazolu
PL08708929T PL2118099T3 (pl) 2007-02-13 2008-02-13 Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11170200T PL2366703T3 (pl) 2007-02-13 2008-02-13 Postać polimorficzna pochodnej 2-amino-(nitroarylo)-tiazolu

Country Status (23)

Country Link
US (3) US8153792B2 (pl)
EP (2) EP2118099B1 (pl)
JP (2) JP5568312B2 (pl)
KR (1) KR20090110851A (pl)
CN (2) CN101657446B (pl)
AR (1) AR065337A1 (pl)
AT (1) ATE515506T1 (pl)
AU (1) AU2008214679A1 (pl)
BR (1) BRPI0807626B1 (pl)
CA (2) CA2677586C (pl)
ES (2) ES2369617T3 (pl)
HR (2) HRP20110709T1 (pl)
IL (1) IL200320A0 (pl)
MA (1) MA31180B1 (pl)
MX (1) MX2009008665A (pl)
NZ (1) NZ578944A (pl)
PL (2) PL2366703T3 (pl)
RU (2) RU2456285C2 (pl)
SI (2) SI2366703T1 (pl)
TN (1) TN2009000342A1 (pl)
TW (1) TWI406862B (pl)
WO (1) WO2008098949A2 (pl)
ZA (1) ZA200905981B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
WO2011092273A1 (en) 2010-01-28 2011-08-04 Ab Science Treatment of gist with masitinib
WO2011092338A1 (en) 2010-02-01 2011-08-04 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AR080380A1 (es) 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
US8906357B2 (en) 2010-04-20 2014-12-09 Ab Science Treatment of multiple sclerosis with masitinib
AR081772A1 (es) 2010-06-02 2012-10-17 Ab Science Tratamiento de la artritis reumatoide con masitinib
WO2012059526A1 (en) 2010-11-05 2012-05-10 Ab Science Treatment of mastocytosis with masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
US9078894B2 (en) 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
WO2012136732A1 (en) 2011-04-08 2012-10-11 Ab Science Treatment of multiple myeloma with masitinib
MX369999B (es) 2012-10-04 2019-11-28 Ab Science Uso de masitinib en combinación con gemcitabina para el tratamiento de cáncer pancreatico en subpoblaciones de pacientes identificados en base al factor predictor de la intensidad de dolor.
TW201605449A (zh) 2013-12-02 2016-02-16 Ａｂ化學公司 馬賽替尼治療結腸直腸癌的用途
EP2886543A1 (en) 2013-12-18 2015-06-24 Sandoz Ag Crystalline form of mastinib mesylate
WO2015185958A1 (en) 2014-06-02 2015-12-10 Ab Science Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
CN105585556A (zh) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 一种伊马替尼的合成方法
WO2017016512A1 (zh) * 2015-07-29 2017-02-02 苏州晶云药物科技有限公司 马赛替尼甲磺酸盐的新晶型及其制备方法
WO2017060308A1 (en) 2015-10-05 2017-04-13 Ab Science Treatment of severe systemic mastocytosis with masitinib
SG11201808106YA (en) 2016-03-25 2018-10-30 Ab Science Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP3601278B1 (en) 2017-03-31 2022-10-26 Sandoz AG Crystalline form of masitinib
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
US12472164B2 (en) 2019-11-22 2025-11-18 Ab Science Masitinib for the treatment of sickle cell disease
EP3831384A1 (en) 2019-12-02 2021-06-09 AB Science Use of masitinib for the treatment of eosinophilic asthma
KR20220143020A (ko) 2020-02-20 2022-10-24 에이비 사이언스 다발 경화증 환자 하위집단의 치료를 위한 마시티닙
EP4132528A1 (en) 2020-04-10 2023-02-15 AB Science Use of masitinib for the treatment of coronavirus disease 2019 (covid-19)
KR20230125804A (ko) 2020-12-16 2023-08-29 에이비 사이언스 알츠하이머병의 치료를 위한 마시티닙
PL4175639T3 (pl) 2021-05-17 2024-02-05 Ab Science Masitinib w leczeniu nowotworu gruczołu krokowego opornego na kastrację
CN115850258B (zh) * 2022-12-27 2024-09-24 东北林业大学 一种马赛替尼的合成方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299087A (en) * 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
PL336990A1 (en) * 1997-05-22 2000-07-31 Searle & Co 3(5)-heteroaryl group substituted pyrazoles as inhibitors of kinase p 38
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6569878B1 (en) * 1997-10-27 2003-05-27 Agouron Pharmaceuticals Inc. Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
IL148385A0 (en) * 1999-09-10 2002-09-12 Merck & Co Inc Tyrosine kinase inhibitors
DE60227709D1 (de) 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
EP1401429A2 (en) 2001-06-29 2004-03-31 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
CA2452366A1 (en) 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
WO2003002108A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
JP2004530722A (ja) 2001-06-29 2004-10-07 アブ サイエンス 骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
CA2452371A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
CA2452167A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
CA2461182A1 (en) 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
JP2005511596A (ja) 2001-09-20 2005-04-28 アブ サイエンス ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法
JP2005507916A (ja) 2001-09-20 2005-03-24 アブ サイエンス 細菌感染症を治療するための、強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用方法
ATE408407T1 (de) 2002-02-27 2008-10-15 Ab Science Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
EP1478380B1 (en) 2002-02-27 2006-08-02 AB Science Use of tyrosine kinase inhibitors for treating cns disorders
PL373842A1 (pl) * 2002-05-29 2005-09-19 Amgen Inc. Pochodne 2-okso-1,3,4-trihydrochinazolinylowe przeznaczone do leczenia chorób związanych z proliferacją komórek
MXPA05001277A (es) * 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
CA2515215A1 (en) * 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20080025916A1 (en) 2003-02-27 2008-01-31 Ab Science Tailored Treatment Suitable for Different Forms of Mastocytosis
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
BRPI0413005A (pt) * 2003-07-29 2006-09-26 Irm Llc compostos e composições como inibidores da proteìna cinase
DE602004013792D1 (de) 2003-08-15 2008-06-26 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
US7363881B2 (en) 2003-11-06 2008-04-29 Nova-Tech Engineering, Inc. Beak treatment with tongue protection
DK1702917T3 (da) * 2003-12-25 2017-11-13 Nippon Shinyaku Co Ltd Amidderivat og medicin
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
TW200702876A (en) * 2005-07-04 2007-01-16 Avermedia Tech Inc Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

Also Published As

Publication number Publication date
TN2009000342A1 (en) 2010-12-31
RU2009132186A (ru) 2011-03-20
IL200320A0 (en) 2010-04-29
TW200848419A (en) 2008-12-16
MX2009008665A (es) 2009-08-21
RU2491286C1 (ru) 2013-08-27
CA2970628A1 (en) 2008-08-21
HRP20110709T1 (hr) 2011-11-30
SI2118099T1 (sl) 2011-11-30
EP2366703B1 (en) 2014-07-30
ATE515506T1 (de) 2011-07-15
TWI406862B (zh) 2013-09-01
CN103342701A (zh) 2013-10-09
CA2970628C (en) 2019-08-27
ZA200905981B (en) 2010-11-24
US8153792B2 (en) 2012-04-10
BRPI0807626A2 (pt) 2014-11-25
AR065337A1 (es) 2009-06-03
CN103342701B (zh) 2016-09-21
BRPI0807626B1 (pt) 2022-03-03
MA31180B1 (fr) 2010-02-01
US20100121063A1 (en) 2010-05-13
HRP20140986T1 (hr) 2014-11-21
JP2010518141A (ja) 2010-05-27
US20120196871A1 (en) 2012-08-02
CA2677586A1 (en) 2008-08-21
WO2008098949A3 (en) 2008-10-02
JP5784073B2 (ja) 2015-09-24
JP5568312B2 (ja) 2014-08-06
CN101657446B (zh) 2013-05-15
RU2456285C2 (ru) 2012-07-20
US8940894B2 (en) 2015-01-27
JP2013177437A (ja) 2013-09-09
EP2118099B1 (en) 2011-07-06
EP2118099A2 (en) 2009-11-18
AU2008214679A1 (en) 2008-08-21
CA2677586C (en) 2017-07-25
ES2522169T3 (es) 2014-11-13
EP2366703A1 (en) 2011-09-21
ES2369617T3 (es) 2011-12-02
KR20090110851A (ko) 2009-10-22
CN101657446A (zh) 2010-02-24
PL2366703T3 (pl) 2015-02-27
US20130289045A1 (en) 2013-10-31
NZ578944A (en) 2011-03-31
WO2008098949A2 (en) 2008-08-21
US8492545B2 (en) 2013-07-23
SI2366703T1 (sl) 2014-10-30

Similar Documents

Publication Publication Date Title
ZA200905981B (en) Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
ZA201002513B (en) Process for the preparation of compounds useful as inhibitors of sglt
HRP20170255T1 (hr) Postupak za pripremu spojeva korisnih kao inhibitori sglt-a
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
IL206286A0 (en) Thiazole derivatives used as pi 3 kinase inhibitors
PL2021335T3 (pl) Związki heterocykliczne jako inhibitory kinazy C-FMS
SI3354650T1 (sl) Spojine, uporabne kot zaviralci ATR kinaze
ZA201103411B (en) Compounds useful as inhibitors of atr kinase
IL194356A0 (en) Novel cyclobutyl compounds as kinase inhibitors
IL202505A0 (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as met kinase inhibitors for the treatment of tumors
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA200903889B (en) Process for the synthesis of moxifloxacin hydrochloride
IL210573A0 (en) Compounds as kinase inhibitors
ZA201000482B (en) Process for the synthesis of e1 activating enzyme inhibitors
IL201245A0 (en) An improved process for the synthesis of solifenacin
GB0702854D0 (en) Method for the synthesis of sucrose-6-esters
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
EP2291077A4 (en) METHOD OF MANUFACTURING RHO-KINASE INHIBITOR COMPOUNDS
GB2459413B (en) Methods for the synthesis of perfluoroparacyclophane
EP2170902A4 (en) IMPROVED METHOD FOR SYNTHESIS OF OLANZAPINE
HK1135962A (en) Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
ZA200802990B (en) Process for the synthesis of compounds for selectin inhibition